InflaRx N.V. company info

What does InflaRx N.V. do?
InflaRx N.V. (FRANKFURT:A2H7A5), (NASDAQ:IFRX) is a pioneering biotech company focused on the development of novel therapies for the treatment of inflammatory diseases using its proprietary anti-human complement factor C5a technology. With a passion for innovation, InflaRx is actively engaged in advancing a diverse pipeline of treatments aimed at addressing severe and life-threatening diseases. The company's flagship project includes developing a first-in-class anti-C5a monoclonal antibody, which has shown promise in clinical trials for conditions such as hidradenitis suppurativa, a chronic skin condition, and severe COVID-19. InflaRx's objective is to harness the power of its technology to bring transformative treatments to patients worldwide, demonstrating its commitment to improving health and making meaningful contributions to the field of medicine.
InflaRx N.V. company media
Company Snapshot

Is InflaRx N.V. a public or private company?

key
Ownership
Public

How many people does InflaRx N.V. employ?

people
Employees
62

What sector is InflaRx N.V. in?

pie chart
Sector
Health Care

Where is the head office for InflaRx N.V.?

location pin
Head Office
Jena, Germany

What year was InflaRx N.V. founded?

founded flag
Year Founded
2007
What does InflaRx N.V. specialise in?
/Therapeutic Antibodies /Inflammatory Diseases /Clinical Trials /IFX-1 Product /Biopharmaceutical Company /Medical Research

What are the products and/or services of InflaRx N.V.?

Overview of InflaRx N.V. offerings
Vilobelimab (IFX-1) - a first-in-class anti-human complement factor C5a monoclonal antibody, targeting severe autoimmune and inflammatory diseases.
Pexelizumab Collaboration - exploring the development of a complement inhibitor for cardiovascular diseases.
COVID-19 Treatment Efforts - researching therapies using its proprietary anti-inflammatory agents.
IFX-2 - a pipeline project aimed at treating chronic inflammatory diseases by targeting complement system components.
Oncology Program - investigating the role of complement activation in cancer immunotherapy.
Complement Diagnostics - developing diagnostic tools to measure complement activation in various diseases.

Who is in the executive team of InflaRx N.V.?

InflaRx N.V. leadership team
  • Dr. Niels C. Riedemann M.D., Ph.D.
    Dr. Niels C. Riedemann M.D., Ph.D.
    Co-Founder, CEO & Executive Director
  • Prof. Renfeng  Guo M.D.
    Prof. Renfeng Guo M.D.
    Co-Founder, Chief Scientific Officer & Executive Director
  • Dr. Thomas  Taapken Ph.D.
    Dr. Thomas Taapken Ph.D.
    Chief Financial Officer
  • Ms. Derval  O'Carroll
    Ms. Derval O'Carroll
    Senior VP and Global Head of Regulatory Affairs & Compliance
  • Dr. Camilla  Chong M.D.
    Dr. Camilla Chong M.D.
    Chief Medical Officer
  • Mr. Jan  Medina CFA
    Mr. Jan Medina CFA
    Head of Investor Relations & VP
  • Mr. Christian  Schmid
    Mr. Christian Schmid
    VP and Head of Legal Affairs & General Counsel
  • Ms. Nicole  Bertsch
    Ms. Nicole Bertsch
    Senior Director & Head of Human Resources